Trial Profile

Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary) ; Lurbinectedin (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms LURBIMUNE

Most Recent Events

14 Jun 2024 This trial has been Discontinued in France (End date: 2024-05-31) according to European Clinical Trials Database record.
04 Jun 2024 Planned End Date changed from 1 Apr 2026 to 31 May 2024.
04 Jun 2024 Planned primary completion date changed from 1 Oct 2024 to 31 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com